Document:

EXHIBIT 10.1

                              DIRECTOR'S AGREEMENT

            This  Director's  Agreement  (this  "Agreement") is made and entered
      into as of the 23rd day of August,  2004, (the "Effective  Date"),  by and
      between  David  McWilliams  (hereinafter  referred to as  "Director")  and
      PharmaFrontiers Corp. ("PharmaFrontiers").

                                   WITNESSETH:

            WHEREAS,  the shareholders of PharmaFrontiers wish to elect Director
      to serve on the Board of Directors (the "Board") of  PharmaFrontiers,  and
      Director  has agreed to serve at the pleasure of the  shareholders  and on
      the terms and conditions below; and

            WHEREAS,  PharmaFrontiers'  success  requires the  protection of its
      intellectual property, proprietary information and goodwill;

            NOW, THEREFORE,  the parties hereto,  intending to be legally bound.
      agree as follows:

      1.    Appointment as Director

            PharmaFrontiers   shall   appoint   Director   to   the   Board   of
      PharmaFrontiers  at  the  next  meeting  of  the  Board,  and,  upon  such
      appointment, Director agrees that Director will devote the amount of time,
      skill,  and efforts  during the term of this  Agreement  to the affairs of
      PharmaFrontiers  as may be  reasonably  requested and required of Director
      and in accordance with the dudes and obligations imposed upon directors of
      corporations by applicable law.

      2.    Compensation

            PharmaFrontiers  shall  compensate  Director  for  his  expenses  in
      attending and  participating  in meetings of the Board.  All  compensation
      paid Director shall be subject to such payroll and withholding  deductions
      as may be required by law or the policies of PharmaFrontiers.

      3.    Confidential and Proprietary Information; Documents

            3.1  PharmaFrontiers  shall provide Director with information deemed
      secret and  confidential by  PharmaFrontiers.  Such secret or confidential
      information or know-how of  PharmaFrontiers  (referred to  collectively as
      "Confidential   Information")  shall  include,  without  limitation,   the
      following:  the status and plans for research and development;  materials,
      cells,  tissues, and other biological samples and specimens;  cell banking
      methods,  apparatus, and services; pending and planned patent applications
      (until published by the Patent Office);  invention  disclosures;  research
      and technical data and information;  methods of creating,  preparing,  and
      using stem cells and other biological materials;  license, sublicense, and

<PAGE>

      other information;  contributor  information;  strategies,  costs, prices,
      uses,  applications  of products  and  services;  results of and data from
      investigations  or  experiments;  all  apparatus,   products,   processes,
      compositions,   samples,  formulas,  computer  programs,  pricing  policy,
      financial  information,  and  methods  of doing  business;  policy  and/or
      procedure  manuals,   training  and  recruiting   procedures;   accounting
      procedures;  the status and content of PharmaFrontiers' contracts with its
      contributors,   clients,   and   customers;    PharmaFrontiers'   business
      philosophy,  and servicing  methods and techniques;  all at any time used,
      developed,  or investigated by PharmaFrontiers,  before or during the term
      of this  Agreement,  which are not  generally  available  to the public or
      which are maintained as confidential by PharmaFronteirs.

            3.2 Director  recognizes  and  acknowledges  that Director will have
      access to certain information of PharmaFrontiers  that is confidential and
      proprietary   and   constitutes    valuable   and   unique   property   of
      PharmaFrontiers.  Director  agrees  that  Director  will not at any  time,
      either  during or subsequent  to the term of this  Agreement,  disclose to
      others,  use,  copy  or  permit  to be  copied,  except  in  pursuance  of
      Director's duties on behalf of PharmaFrontiers, its successors, assigns or
      nominees,  or as required by the order of any tribunal having jurisdiction
      or by mandatory provisions of applicable law, any Confidential Information
      or know-how of  PharmaFrontiers  without the prior written  consent of the
      Board  of   PharmaFrontiers.   Director  further  agrees  to  maintain  in
      confidence any  confidential  information  of third parties  received as a
      result of Director's relationship with PharmaFrontiers.

            3.3 Director further agrees to deliver to  PharmaFrontiers  promptly
      after his resignation,  removal or failure to be nominated or elected as a
      member of the Board, all biological materials  correspondence,  memoranda,
      notes,  records,  drawings,   sketches,  plans,  customer,  client  and/or
      contributor lists, product compositions, or other documents and all copies
      thereof (all of which are hereafter referred to as the "Documents"), made,
      composed or received by Director, solely or jointly with others, and which
      are in Director's  possession,  custody, or control at such date and which
      are related in any manner to the past, present, or anticipated business of
      PharmaFrontiers.

            3.4 Director  further agrees that Director will not, during the term
      of this  Agreement,  and on behalf of  PharmaFrontiers  accept or agree to
      receive  from persons not employed by  PharmaFrontiers,  any  confidential
      information not belonging to PharmaFrontiers, unless prior to such receipt
      or acceptance a valid agreement has been executed between  PharmaFrontiers
      and the disclosing party that states that PharmaFrontiers will not be in a
      confidential  relationship  with the disclosing  party.  Director  further
      agrees that  Director  will not use in  violation  of any  confidentiality
      obligation binding upon Director any confidential information belonging to
      Director's employer or any former employer, or any other third parties.

            3.5 In the  event of a breach  or  threatened  breach  of any of the
      provisions  of  Section  4, or an  breach  by  Director  of his  fiduciary
      obligation to PharmaFrontiers and its shareholders,  PharmaFrontiers shall
      be entitled to an injunction ordering the return of such Documents and any
      and all copies thereof and restraining  Director from using or disclosing,
      for Director's  benefit or the benefit of others, in whole or in part, any
      Confidential  Information,  including but not limited to the  Confidential
      Information which such Documents contain,  constitute, or embody. Director
      further  agrees  that  any  breach  or  threatened  breach  of  any of the

<PAGE>

      provisions of Section 4 would cause irreparable  injury to PharmaFrontiers
      for which it would have no adequate remedy at law. Nothing herein shall be
      construed as prohibiting  PharmaFrontiers from pursuing any other remedies
      available to it for any such breach or  threatened  breach,  including the
      recovery of damages.

      4.    Noncompetition/No-Hire Agreement

            4.1 Director  agrees that, from the Effective Date until a period of
      one (l) year following the date of his  resignation  removal or failure to
      be  nominated  or elected as a member of the Board,  (the  "Noncompetition
      Period"), Director will not directly or indirectly, either as an employee,
      employer,   consultant,  agent,  principal,  partner,  corporate  officer,
      director, or in any other individual or representative capacity, engage or
      participate in any "Competitive Business" anywhere in the United States of
      America, Canada or the European Union (the "Noncompetition Territory"). As
      used  herein,  a  "Competitive  Business"  is  defined  as  any  business,
      including  those  relating to stern cells or cell banking,  which provides
      the same or  substantially  the same  products,  services  or  licenses to
      intellectual  property  rights,  in whole or in part,  as are  provided by
      PharmaFrontiers during the term of this Agreement.

            4.2 Director  further agrees that during the  Noncompetition  Period
      and within the  Noncompetition  Territory  Director will not,  directly or
      indirectly, either as an employee, employer, consultant, agent, principal,
      partner,  corporate  officer,  director,  or in any  other  individual  or
      representative capacity, call on, solicit, recruit, or attempt to call on,
      solicit,  or  recruit,  or  attempt  to  hire  any  of  the  employees  of
      PharmaFrontiers,  regardless of whether for the benefit of the Director or
      for any other person, firm, or corporation.

            4.3 Director shall not during the  Noncompetition  Period and within
      the Noncompetition Territory, either directly or indirectly (i) make known
      to  any   Competitive   Business  the  names  and   addresses  of  any  of
      PharmaFrontiers' customers or contacts or any other information pertaining
      to such persons or businesses or (ii) call on,  solicit,  or take away, or
      attempt  to  call  on,  solicit  or  take  away  any of the  customers  of
      PharmaFrontiers  with whom Director became  acquainted  during  Director's
      service as a member of PharmaFrontiers'  Board,  regardless of whether for
      the benefit of the Director or for any other person, firm or corporation.

            4.4  Director   agrees  that  this  Section  is  ancillary  to  this
      Agreement,  and  Director  acknowledges  that the  consideration  given by
      PharmaFrontiers for this Agreement includes PharmaFrontiers'  agreement to
      provide to the Director access to the Confidential  Information.  Further,
      the  existence  of any  claim or  cause  of  action  of  Director  against
      PharmaFrontiers or any officer,  director, or employee of PharmaFrontiers,
      whether predicated on this Agreement or otherwise,  shall not constitute a

<PAGE>

      defense to the  enforcement  by  PharmaFrontiers  of Director's  covenants
      contained in this Agreement. In addition, this Agreement shall continue to
      be binding upon Director in accordance with its terms, notwithstanding the
      termination of this Agreement.

            4.5 Director agrees that Director's  breach or violation,  or threat
      thereof, of this covenant not to compete shall entitle PharmaFrontiers, as
      a matter of right, to an injunction without the necessity of posting bond,
      issued by any court of competent jurisdiction,  restraining any further or
      continued  breach  or  violation  of  this  covenant.  Such  right  to  an
      injunction shall be cumulative and in addition to, and not in lieu of, any
      other remedies to which  PharmaFrontiers  may show itself justly entitled.
      Further, during any period in which Director is in breach of this covenant
      not to compete,  the time period of this covenant shall be extended for an
      amount of time that Director is in breach.

      5.    Inventions and Other Intellectual Property

            5.1  Director  agrees to hold in  complete  trust for the benefit of
      PharmaFrontiers,  and to disclose and fully to PharmaFrontiers in writing,
      and hereby assigns, and binds Director's heirs, executors, administrators,
      and all legal  representatives to assign, to  PharmaFrontiers  any and all
      inventions,  discoveries,  ideas,  concepts,  improvements,  copyrightable
      works, biological materials,  and other developments (all of the above are
      collectively   referred  to  as  the  "Developments")   conceived,   made,
      discovered or developed by him, solely or jointly with others,  during the
      term of this Agreement,  whether during or outside of usual wet-king hours
      and  whether on  PharmaFrontiers'  premises  or not,  which  relate in any
      manner to the past,  present or anticipated  business of  PharmaFrontiers.
      The parties  agree that,  if Director is an inventor as determined by U.S.
      patent law for any  invention,  Director  shall be named as an inventor in
      connection  with  any  patent  application  therefore.  Any and  all  such
      Developments shall be the sole and exclusive property of  PharmaFrontiers,
      whether patentable,  copyrightable,  or neither,  and Director agrees that
      Director will assist and fully cooperate in every way, at PharmaFrontiers'
      expense,  in  securing,  maintaining,  and  enforcing,  for the benefit of
      PharmaFrontiers  or its  designee,  patents,  copyrights or other types of
      proprietary or intellectual  property  protection for such Developments in
      any and all countries.  Director  acknowledges and agrees that any and all
      such Developments  conceived,  created, or authored by him is a "work made
      for hire," as defined by the federal  copyright  laws,  and  therefore all
      copyrights in and to such works are and will be owned by  PharmaFrontiers.
      To the extent that Director authors any  copyrightable  work in any medium
      during the term of this Agreement  which relates or pertains in any way to
      PharmaFrontiers or any of the operations or activities of either and which
      was is held not a work made for hire.  Director  hereby assigns all right.

<PAGE>

      title, and interest, including but not limited to all rights of copyright,
      in and to such works to  PharmaFrontiers.  Within six months following the
      termination of this Agreement,  and without limiting the generality of the
      foregoing, any Development of the Director relating to any PharmaFrontiers
      subject matter on which Director worked or was informed during the term of
      this Agreement shall be  conclusively  presumed to have been conceived and
      made prior to the  termination  of this  Agreement  (unless  the  Director
      clearly proves that such  Development was conceived and made following the
      termination  of this  Agreement),  and shall  accordingly  belong,  and be
      assigned to PharmaFrontiers and shall be subject to this Agreement.

            5.2 Without  limiting the foregoing,  Director agrees at the request
      of   PharmaFrontiers    (but   without   additional    compensation   from
      PharmaFrontiers   during  Director's  employment  by  PharmaFrontiers)  to
      execute   any  and  all  papers  and   perform   all  lawful   acts  which
      PharmaFrontiers deems necessary for the preparation,  filing, prosecution,
      and  maintenance  of  applications  for United States and foreign  letters
      patent or for United States and foreign  copyrights,  on the Developments,
      and to execute such  instruments  as are necessary or convenient to assign
      to  PharmaFrontiers,  its  successors,  assigns  or  nominees,  all of the
      Director's right, title, and interest in the Developments and the like, so
      as to establish, maintain or perfect, in PharmaFrontiers,  its successors,
      assigns  or  nominees,  the  entire  right,  title,  and  interest  to the
      Developments,  and also to  execute  any  instruments  necessary  or which
      PharmaFrontiers  may deem desirable it connection  with any  continuation,
      renewal or  reissue  thereof,  or in the  conduct  of any  proceedings  or
      litigation in regard thereto.

            5.3  All  expenses  incurred  by  the  Director  by  reason  of  the
      performance  of any of the  obligations  set  forth  in  this  Section  on
      Inventions  shall be  borne  by  PharmaFrontiers.  Should  the  Director's
      assistance  be  requested by  PharmaFrontiers  after  termination  of this
      Agreement,  PharmaFrontiers  would compensate the Director at a reasonable
      rate.

      6.    Conflicts of Interest

            6.1 In keeping with Director's  fiduciary duties to PharmaFrontiers,
      Director  agrees that Director shall not,  directly or indirectly,  become
      involved in any conflict of interest,  or upon  discovery  thereof,  allow
      such a conflict to continue. Moreover, Director agrees that Director shall
      promptly  disclose to the Board of  PharmaFrontiers  any facts which might
      involve  any   reasonable   possibility  of  a  conflict  of  interest  as
      PharmaFrontiers  is currently and in the future  configured and practicing
      business.  Director shall maintain the highest  standards of conduct,  and
      shall not do  anything  likely to injure the  reputation  or  goodwill  of
      PharmaFrontiers,  or embarrass or otherwise generate adverse publicity for
      or bring unwanted attention to PharmaFrontiers.

            6.2 It is agreed that any direct or indirect interest in, connection
      with,  or benefit  from any outside  activities,  particularly  commercial
      activities,   which   interest   might   in  any  way   adversely   affect
      PharmaFrontiers  or any of its  subsidiaries  or  affiliates,  involves  a
      possible  conflict  of  interest.  Circumstances  in which a  conflict  of
      interest on the part of Director would or might arise, and which should be
      reported  immediately  by  Director  to  an  officer  of  PharmaFrontiers,
      include,  without limitation,  the following:  (a) ownership of a material
      interest  in,  acting  in any  capacity  for,  or  accepting  directly  or
      indirectly  any payments,  services or loans from a supplier,  contractor,

<PAGE>

      subcontractor,  customer or other entity with which  PharmaFrontiers  does
      business;  (b) misuse of  information  or facilities to which Director has
      access in a manner which will be detrimental to PharmaFrontiers' interest;
      (c) disclosure or other misuse of information of any kind obtained through
      the Director's connection with  PharmaFrontiers;  (d) acquiring or trading
      in, directly or indirectly,  other properties or interests  connected with
      the design, manufacture or marketing of products designed. manufactured or
      marketed by PharmaFrontiers;  (e) the appropriation to the Director or the
      diversion to others,  directly or indirectly,  of any opportunity in which
      it is known or could reasonably be anticipated that PharmaFrontiers  would
      be  interested;  and (f)  the  ownership,  directly  or  indirectly,  of a
      material interest in an enterprise in competition with  PharmaFrontiers or
      its dealers and  distributors or acting as a director,  officer,  partner,
      consultant,  Director or agent of any  enterprise  which is in competition
      with PharmaFrontiers or its dealers or distributors.

      7.    Prior Discoveries

            Director  has no  unpatented  inventions  and  discoveries  made  or
      conceived by Director prior to the Effective Date that relate to stem cell
      isolation, identification and/or expansion and/or cell banking.

      8.    Remedies

            Director and PharmaFrontiers  agree that, because damages at law for
      any  breach  or  nonperformance  of  this  Agreement  by  Director,  while
      recoverable, are and will be inadequate, this Agreement may be enforced in
      equity by specific performance, injunction, accounting or otherwise.

      9.    Miscellaneous

            9.1 This Agreement is made and entered into as of the Effective Date
      and the rights and obligations of the parties hereto shall be binding upon
      the heirs and legal representatives of the Director and the successors and
      assigns  of   PharmaFrontiers.   This   Agreement   may  be   assigned  by
      PharmaFronteirs (including assignment by operation of law to any successor
      to the  business  of  PharmaFronteirs  by merger,  consolidation  or other
      business  combination)  without the consent of Director but is personal to
      the Director and no rights,  duties, and obligations of Director hereunder
      may be assigned  without the consent of  PharmaFrontiers  or its  assigns,
      which may be granted or withheld in its sole discretion.

            9.2 No waiver or non-action  with respect to any breach by the other
      party of any  provision of this  Agreement,  nor the waiver or  non-action
      with respect to any breach of the  provisions of similar  agreements  with
      other Directors shall be construed to be a waiver of any succeeding breach
      of such provision, or as a waiver of the provision itself.

            9.3  Should any  portions  hereof be held to be invalid or wholly or
      partially  unenforceable,  such holding  shall not  invalidate or void the
      remainder  of  this  Agreement.   The  portions  held  to  be  invalid  or
      unenforceable  shall be revised and reduced in scope so as to be valid and

<PAGE>

      enforceable,  or, if such is not  possible,  then such  portions  shall be
      deemed to have been wholly  excluded  with the same force and effect as it
      if had never been included herein.

            9.4 Director's  obligations under this Agreement to  PharmaFrontiers
      shall survive Director's  resignation,  removal or failure to be nominated
      or elected as a member of the Board of PharmaFronteirs.

            9.5 This Agreement supersedes, replaces and merges any and all prior
      and  contemporaneous  understandings,   representations,   agreements  and
      discussions relating to the same or similar subject matter as that of this
      Agreement  between Director and  PharmaFronteirs  and constitutes the sole
      and entire agreement between the Director and PharmaFrontiers with respect
      to the subject matter of this Agreement.

            9.6 The laws of the State of Texas,  excluding  any conflicts of law
      rule or principle that might  otherwise  refer to the  substantive  law of
      another jurisdiction, will govern the interpretation,  validity and effect
      of this  Agreement  without  regard to the place of execution or the place
      for performance  thereof,  and PharmaFronteirs and Director agree that the
      state and federal  courts in Harris  county,  Texas,  shall have  personal
      jurisdiction  and venue  over  PharmaFrontiers  and  Director  to hear all
      disputes  arising under this  Agreement.  This Agreement is to be at least
      partially performed in Harris County, Texas.

            9.7 All  notices  and other  communications  required  or  permitted
      hereunder or necessary or convenient in  connection  herewith  shall be in
      writing and shall be deemed to have given when mailed by  registered  mail
      or certified mail, return receipt requested, as follows:

            If to PharmaFronteirs, to:

            Mr. Warren C. Lau PharmaFrontiers  Corporation 18205 Burkhardt
            Road Tomball, Texas 77377

            If to Director, to:

            David McWilliams

or to such other  addresses as either party may designate by notice to the other
party hereto in the manner specified in this section.

<PAGE>

            9.8 This Agreement may not be changed or terminated  orally,  and no
      change,  termination  or  waiver  of  this  Agreement  or of  any  of  the
      provisions  herein  contained  shall be binding unless made in writing and
      signed  by  both  parties,  and  in the  case  of  PharmaFrontiers,  by an
      authorized officer of PharmaFrontiers. Any change or changes, from time to
      time,  in  Director's  compensation  shall  not be deemed to be, a change,
      termination or waiver of this Agreement or of any of the provisions herein
      contained.

      IN WITNESS  WHEREOF,  the undersigned have hereby caused this Agreement to
      be effective as of the date first written above.

                                   PharmaFronteirs Corp., a Texas Corporation

                                   By: /s/ Warren Lau
                                       -------------------------------
                                       Warren Lau, President

                                   By: /s/David McWilliams
                                       -------------------------------
                                       David McWilliamsDIRECTOR'S AGREEMENT

      This Director's  Agreement (this  "Agreement") is made and entered into as
of the 23rd day of August,  2004, (the "Effective  Date"),  by and between Brian
Rodriquez  (hereinafter  referred to as "Director")  and  PharmaFrontiers  Corp.
("PharmaFrontiers").

                                   WITNESSETH:

      WHEREAS,  the  shareholders of  PharmaFrontiers  wish to elect Director to
serve on the Board of Directors (the "Board") of  PharmaFrontiers,  and Director
has agreed to serve at the  pleasure  of the  shareholders  and on the terms and
conditions below; and

      WHEREAS,   PharmaFrontiers'   success   requires  the  protection  of  its
intellectual property, proprietary information and goodwill;

      NOW, THEREFORE,  the parties hereto,  intending to be legally bound. agree
as follows:

1.    Appointment as Director

      PharmaFrontiers  shall appoint Director to the Board of PharmaFrontiers at
the next meeting of the Board, and, upon such appointment,  Director agrees that
Director will devote the amount of time,  skill,  and efforts during the term of
this Agreement to the affairs of PharmaFrontiers as may be reasonably  requested
and  required  of  Director  and in  accordance  with the dudes and  obligations
imposed upon directors of corporations by applicable law.

2.    Compensation

      As compensation  for serving as a member of the Board of  PharmaFrontiers,
PharmaFrontiers  agrees upon the  execution  and  delivery of this  Agreement to
PharmaFrontiers,  to issue to Director an option for 80,000 shares of the common
stock of  PharmaFrontiers.  The Option Exercise Price per share: shall initially
be $10.00,  and reduced to equal the weighted  average gross  offering  price of
shares of Common  Stock issued in equity  financings  by the Company on or after
August 1, 2004 resulting in gross proceeds  raised by the Company of at least $5
million in one or more series of  transactions  of Common  Stock or Common Stock
equivalents  if such  weighted  average  offering  price  is less  than  $10.00;
however,  in no  event  shall  the  exercise  price  be lower  than  $5.00.  The
Expiration date for vesting: August 20, 2009. The Expiration date for exercising
vested Options: August 20, 2009. In addition,  PharmaFrontiers will pay Director
the sum of $15,000 annually paid  semi-monthly for each year the Director serves
as a Director  of  PharmaFrontiers,  which  shall  compensate  Director  for his
expenses  in  attending  and   participating  in  meetings  of  the  Board.  All
compensation  paid  Director  shall be subject to such  payroll and  withholding
deductions as may be required by law or the policies of PharmaFrontiers.

<PAGE>

3.    Confidential and Proprietary Information; Documents

      3.1 PharmaFrontiers  shall provide Director with information deemed secret
and confidential by PharmaFrontiers.  Such secret or confidential information or
know-how  of   PharmaFrontiers   (referred  to  collectively  as   "Confidential
Information") shall include,  without limitation,  the following: the status and
plans  for  research  and  development;  materials,  cells,  tissues,  and other
biological samples and specimens; cell banking methods, apparatus, and services;
pending and planned patent  applications (until published by the Patent Office);
invention disclosures;  research and technical data and information;  methods of
creating,  preparing,  and using  stem  cells and  other  biological  materials;
license, sublicense, and other information; contributor information; strategies,
costs, prices, uses, applications of products and services;  results of and data
from  investigations  or  experiments;  all  apparatus,   products,   processes,
compositions,  samples,  formulas,  computer programs, pricing policy, financial
information,  and methods of doing business;  policy and/or  procedure  manuals,
training  and  recruiting  procedures;  accounting  procedures;  the  status and
content  of  PharmaFrontiers'  contracts  with its  contributors,  clients,  and
customers;  PharmaFrontiers'  business  philosophy,  and  servicing  methods and
techniques; all at any time used, developed, or investigated by PharmaFrontiers,
before or during the term of this Agreement,  which are not generally  available
to the public or which are maintained as confidential by PharmaFrontiers.

      3.2 Director recognizes and acknowledges that Director will have access to
certain information of PharmaFrontiers  that is confidential and proprietary and
constitutes  valuable and unique  property of  PharmaFrontiers.  Director agrees
that Director  will not at any time,  either during or subsequent to the term of
this Agreement,  disclose to others, use, copy or permit to be copied, except in
pursuance of Director's  duties on behalf of  PharmaFrontiers,  its  successors,
assigns  or  nominees,  or as  required  by the  order  of any  tribunal  having
jurisdiction  or by mandatory  provisions  of applicable  law, any  Confidential
Information or know-how of PharmaFrontiers  without the prior written consent of
the Board of PharmaFrontiers.  Director further agrees to maintain in confidence
any confidential information of third parties received as a result of Director's
relationship with PharmaFrontiers.

      3.3 Director further agrees to deliver to  PharmaFrontiers  promptly after
his  resignation,  removal or failure to be  nominated or elected as a member of
the Board, all biological materials correspondence,  memoranda,  notes, records,
drawings,  sketches,  plans, customer,  client and/or contributor lists, product
compositions,  or other  documents  and all  copies  thereof  (all of which  are
hereafter  referred  to as the  "Documents"),  made,  composed  or  received  by
Director, solely or jointly with others, and which are in Director's possession,
custody,  or  control  at such date and which are  related  in any manner to the
past, present, or anticipated business of PharmaFrontiers.

<PAGE>

      3.4 Director  further  agrees that Director  will not,  during the term of
this Agreement, and on behalf of PharmaFrontiers accept or agree to receive from
persons not  employed  by  PharmaFrontiers,  any  confidential  information  not
belonging to PharmaFrontiers, unless prior to such receipt or acceptance a valid
agreement has been executed  between  PharmaFrontiers  and the disclosing  party
that states that PharmaFrontiers will not be in a confidential relationship with
the  disclosing  party.  Director  further  agrees that Director will not use in
violation  of  any   confidentiality   obligation   binding  upon  Director  any
confidential   information  belonging  to  Director's  employer  or  any  former
employer, or any other third parties.

      3.5 In the event of a breach or threatened breach of any of the provisions
of  Section  4,  or an  breach  by  Director  of  his  fiduciary  obligation  to
PharmaFrontiers  and its shareholders,  PharmaFrontiers  shall be entitled to an
injunction  ordering the return of such Documents and any and all copies thereof
and restraining Director from using or disclosing, for Director's benefit or the
benefit of others, in whole or in part, any Confidential Information,  including
but not limited to the Confidential  Information  which such Documents  contain,
constitute,  or embody.  Director  further  agrees that any breach or threatened
breach of any of the provisions of Section 4 would cause  irreparable  injury to
PharmaFrontiers  for which it would  have no  adequate  remedy  at law.  Nothing
herein shall be construed as prohibiting PharmaFrontiers from pursuing any other
remedies available to it for any such breach or threatened breach, including the
recovery of damages.

      4.    Noncompetition/No-Hire Agreement

      4.1 Director  agrees that,  from the Effective  Date until a period of one
(l)  year  following  the  date of his  resignation  removal  or  failure  to be
nominated or elected as a member of the Board,  (the  "Noncompetition  Period"),
Director  will not  directly or  indirectly,  either as an  employee,  employer,
consultant,  agent, principal,  partner,  corporate officer, director, or in any
other  individual  or  representative  capacity,  engage or  participate  in any
"Competitive  Business" anywhere in the United States of America,  Canada or the
European Union (the "Noncompetition  Territory"). As used herein, a "Competitive
Business" is defined as any business, including those relating to stern cells or
cell  banking,  which  provides  the same or  substantially  the same  products,
services or licenses to intellectual  property  rights,  in whole or in part, as
are provided by PharmaFrontiers during the term of this Agreement.

      4.2  Director  further  agrees that during the  Noncompetition  Period and
within the  Noncompetition  Territory Director will not, directly or indirectly,
either  as  an  employee,  employer,   consultant,  agent,  principal,  partner,
corporate  officer,  director,  or in any  other  individual  or  representative
capacity, call on, solicit, recruit, or attempt to call on, solicit, or recruit,
or  attempt  to hire any of the  employees  of  PharmaFrontiers,  regardless  of
whether  for the  benefit of the  Director  or for any other  person,  firm,  or
corporation.

      4.3  Director  shall not during the  Noncompetition  Period and within the
Noncompetition  Territory,  either  directly or indirectly (i) make known to any
Competitive  Business  the  names  and  addresses  of  any  of  PharmaFrontiers'
customers  or contacts or any other  information  pertaining  to such persons or

<PAGE>

businesses  or (ii) call on,  solicit,  or take  away,  or  attempt  to call on,
solicit or take away any of the customers of PharmaFrontiers  with whom Director
became  acquainted  during  Director's  service as a member of  PharmaFrontiers'
Board,  regardless  of whether for the benefit of the  Director or for any other
person, firm or corporation.

      4.4 Director agrees that this Section is ancillary to this Agreement,  and
Director  acknowledges that the consideration  given by PharmaFrontiers for this
Agreement includes PharmaFrontiers'  agreement to provide to the Director access
to the Confidential Information. Further, the existence of any claim or cause of
action of Director against PharmaFrontiers or any officer, director, or employee
of PharmaFrontiers, whether predicated on this Agreement or otherwise, shall not
constitute  a  defense  to the  enforcement  by  PharmaFrontiers  of  Director's
covenants  contained  in this  Agreement.  In  addition,  this  Agreement  shall
continue  to  be  binding   upon   Director  in   accordance   with  its  terms,
notwithstanding the termination of this Agreement.

      4.5  Director  agrees  that  Director's  breach  or  violation,  or threat
thereof,  of this covenant not to compete shall  entitle  PharmaFrontiers,  as a
matter of right, to an injunction  without the necessity of posting bond, issued
by any court of  competent  jurisdiction,  restraining  any further or continued
breach or  violation  of this  covenant.  Such right to an  injunction  shall be
cumulative  and in addition to, and not in lieu of, any other  remedies to which
PharmaFrontiers may show itself justly entitled.  Further,  during any period in
which Director is in breach of this covenant not to compete,  the time period of
this  covenant  shall be  extended  for an amount of time  that  Director  is in
breach.

      5.    Inventions and Other Intellectual Property

      5.1  Director  agrees  to hold  in  complete  trust  for  the  benefit  of
PharmaFrontiers,  and to disclose and fully to PharmaFrontiers  in writing,  and
hereby assigns, and binds Director's heirs, executors,  administrators,  and all
legal  representatives  to assign,  to  PharmaFrontiers  any and all inventions,
discoveries,  ideas,  concepts,  improvements,  copyrightable works,  biological
materials, and other developments (all of the above are collectively referred to
as the "Developments")  conceived,  made, discovered or developed by him, solely
or jointly with others,  during the term of this  Agreement,  whether  during or
outside of usual wet-king hours and whether on PharmaFrontiers' premises or not,
which  relate in any manner to the past,  present  or  anticipated  business  of
PharmaFrontiers.  The  parties  agree  that,  if  Director  is  an  inventor  as
determined by U.S.  patent law for any invention,  Director shall be named as an
inventor in connection with any patent application  therefore.  Any and all such
Developments  shall be the  sole  and  exclusive  property  of  PharmaFrontiers,
whether patentable, copyrightable, or neither, and Director agrees that Director
will assist and fully cooperate in every way, at  PharmaFrontiers'  expense,  in
securing,  maintaining, and enforcing, for the benefit of PharmaFrontiers or its
designee,  patents,  copyrights or other types of  proprietary  or  intellectual
property  protection for such  Developments  in any and all countries.  Director
acknowledges and agrees that any and all such Developments  conceived,  created,
or  authored  by him is a "work  made  for  hire,"  as  defined  by the  federal

<PAGE>

copyright  laws,  and therefore all copyrights in and to such works are and will
be  owned  by   PharmaFrontiers.   To  the  extent  that  Director  authors  any
copyrightable work in any medium during the term of this Agreement which relates
or pertains in any way to PharmaFrontiers or any of the operations or activities
of  either  and which  was is held not a work  made for  hire.  Director  hereby
assigns all right. title, and interest,  including but not limited to all rights
of  copyright,  in and to such  works  to  PharmaFrontiers.  Within  six  months
following the termination of this Agreement, and without limiting the generality
of  the   foregoing,   any   Development   of  the  Director   relating  to  any
PharmaFrontiers  subject matter on which Director  worked or was informed during
the term of this Agreement shall be conclusively presumed to have been conceived
and made prior to the termination of this Agreement (unless the Director clearly
proves that such Development was conceived and made following the termination of
this   Agreement),   and  shall   accordingly   belong,   and  be   assigned  to
PharmaFrontiers and shall be subject to this Agreement.

      5.2 Without  limiting  the  foregoing,  Director  agrees at the request of
PharmaFrontiers (but without additional compensation from PharmaFrontiers during
Director's  employment  by  PharmaFrontiers)  to execute  any and all papers and
perform  all  lawful  acts  which   PharmaFrontiers   deems  necessary  for  the
preparation,  filing,  prosecution,  and maintenance of applications  for United
States and foreign  letters patent or for United States and foreign  copyrights,
on the  Developments,  and to  execute  such  instruments  as are  necessary  or
convenient to assign to  PharmaFrontiers,  its successors,  assigns or nominees,
all of the Director's  right,  title,  and interest in the  Developments and the
like,  so  as  to  establish,  maintain  or  perfect,  in  PharmaFrontiers,  its
successors,  assigns or nominees,  the entire right,  title, and interest to the
Developments,   and  also  to  execute  any   instruments   necessary  or  which
PharmaFrontiers may deem desirable it connection with any continuation,  renewal
or reissue thereof, or in the conduct of any proceedings or litigation in regard
thereto.

      5.3 All expenses  incurred by the Director by reason of the performance of
any of the obligations set forth in this Section on Inventions shall be borne by
PharmaFrontiers.    Should   the   Director's   assistance   be   requested   by
PharmaFrontiers  after  termination  of this  Agreement,  PharmaFrontiers  would
compensate the Director at a reasonable rate.

      6.    Conflicts of Interest

      6.1 In  keeping  with  Director's  fiduciary  duties  to  PharmaFrontiers,
Director agrees that Director shall not, directly or indirectly, become involved
in any conflict of interest, or upon discovery thereof, allow such a conflict to
continue. Moreover, Director agrees that Director shall promptly disclose to the
Board  of   PharmaFrontiers   any  facts  which  might  involve  any  reasonable
possibility of a conflict of interest as PharmaFrontiers is currently and in the

<PAGE>

future configured and practicing  business.  Director shall maintain the highest
standards of conduct,  and shall not do anything likely to injure the reputation
or goodwill of  PharmaFrontiers,  or  embarrass or  otherwise  generate  adverse
publicity for or bring unwanted attention to PharmaFrontiers.

      6.2 It is agreed that any direct or indirect interest in, connection with,
or benefit  from any outside  activities,  particularly  commercial  activities,
which interest might in any way adversely affect  PharmaFrontiers  or any of its
subsidiaries   or  affiliates,   involves  a  possible   conflict  of  interest.
Circumstances  in which a conflict of interest on the part of Director  would or
might arise, and which should be reported  immediately by Director to an officer
of PharmaFrontiers, include, without limitation, the following: (a) ownership of
a material  interest in,  acting in any capacity  for, or accepting  directly or
indirectly  any  payments,  services  or  loans  from  a  supplier,  contractor,
subcontractor,   customer  or  other  entity  with  which  PharmaFrontiers  does
business;  (b) misuse of  information or facilities to which Director has access
in a  manner  which  will  be  detrimental  to  PharmaFrontiers'  interest;  (c)
disclosure  or other  misuse of  information  of any kind  obtained  through the
Director's  connection  with  PharmaFrontiers;  (d)  acquiring  or  trading  in,
directly or indirectly, other properties or interests connected with the design,
manufacture  or  marketing  of products  designed.  manufactured  or marketed by
PharmaFrontiers;  (e) the  appropriation  to the  Director or the  diversion  to
others, directly or indirectly, of any opportunity in which it is known or could
reasonably be anticipated that PharmaFrontiers would be interested;  and (f) the
ownership,  directly or indirectly,  of a material  interest in an enterprise in
competition with  PharmaFrontiers or its dealers and distributors or acting as a
director,  officer,  partner,  consultant,  Director or agent of any  enterprise
which is in competition with PharmaFrontiers or its dealers or distributors.

      7.    Prior Discoveries

      Director has no unpatented inventions and discoveries made or conceived by
Director  prior to the  Effective  Date  that  relate  to stem  cell  isolation,
identification and/or expansion and/or cell banking.

      8.    Remedies

      Director and  PharmaFrontiers  agree that,  because damages at law for any
breach or nonperformance of this Agreement by Director,  while recoverable,  are
and will be  inadequate,  this  Agreement  may be enforced in equity by specific
performance, injunction, accounting or otherwise.

      9.    Miscellaneous

      9.1 This  Agreement is made and entered into as of the Effective  Date and
the rights and obligations of the parties hereto shall be binding upon the heirs
and legal  representatives  of the  Director and the  successors  and assigns of
PharmaFrontiers.  This Agreement may be assigned by  PharmaFrontiers  (including
assignment   by  operation   of  law  to  any   successor  to  the  business  of
PharmaFrontiers by merger,  consolidation or other business combination) without

<PAGE>

the consent of Director but is personal to the  Director and no rights,  duties,
and  obligations  of Director  hereunder may be assigned  without the consent of
PharmaFrontiers  or its  assigns,  which may be granted or  withheld in its sole
discretion.

      9.2 No waiver or non-action  with respect to any breach by the other party
of any provision of this Agreement, nor the waiver or non-action with respect to
any breach of the provisions of similar agreements with other Directors shall be
construed to be a waiver of any  succeeding  breach of such  provision,  or as a
waiver of the provision itself.

      9.3  Should  any  portions  hereof  be held to be  invalid  or  wholly  or
partially unenforceable, such holding shall not invalidate or void the remainder
of this  Agreement.  The portions held to be invalid or  unenforceable  shall be
revised and reduced in scope so as to be valid and  enforceable,  or, if such is
not possible,  then such portions  shall be deemed to have been wholly  excluded
with the same force and effect as it if had never been included herein.

      9.4 Director's  obligations under this Agreement to PharmaFrontiers  shall
survive Director's resignation, removal or failure to be nominated or elected as
a member of the Board of PharmaFrontiers.

      9.5 This Agreement  supersedes,  replaces and merges any and all prior and
contemporaneous  understandings,  representations,  agreements  and  discussions
relating to the same or similar subject matter as that of this Agreement between
Director  and  PharmaFrontiers  and  constitutes  the sole and entire  agreement
between the Director and  PharmaFrontiers  with respect to the subject matter of
this Agreement.

      9.6 The laws of the State of Texas, excluding any conflicts of law rule or
principle  that  might  otherwise  refer  to  the  substantive  law  of  another
jurisdiction,  will  govern  the  interpretation,  validity  and  effect of this
Agreement  without regard to the place of execution or the place for performance
thereof,  and  PharmaFrontiers  and  Director  agree that the state and  federal
courts in Harris county,  Texas, shall have personal jurisdiction and venue over
PharmaFrontiers  and Director to hear all disputes arising under this Agreement.
This Agreement is to be at least partially performed in Harris County, Texas.

      9.7 All notices and other  communications  required or permitted hereunder
or necessary or convenient in connection  herewith shall be in writing and shall
be deemed to have given when mailed by registered mail or certified mail, return
receipt requested, as follows:

      If to PharmaFrontiers, to:

      Mr.  Warren  C.  Lau
      PharmaFrontiers  Corporation
      18205  Burkhardt  Road
      Tomball, Texas 77377

      If to Director, to:

      Brian Rodriquez

or to such other  addresses as either party may designate by notice to the other
party hereto in the manner specified in this section.

<PAGE>

      9.8 This Agreement may not be changed or terminated orally, and no change,
termination  or  waiver of this  Agreement  or of any of the  provisions  herein
contained  shall be binding  unless made in writing and signed by both  parties,
and in the case of PharmaFrontiers, by an authorized officer of PharmaFrontiers.
Any change or changes,  from time to time, in Director's  compensation shall not
be deemed to be, a change,  termination or waiver of this Agreement or of any of
the provisions herein contained.

IN WITNESS  WHEREOF,  the  undersigned  have hereby caused this  Agreement to be
effective as of the date first written above.

                                  PharmaFrontiers Corp., a Texas Corporation

                                  By: /s/ Warren Lau
                                      -------------------------------
                                      Warren Lau, President

                                  By: /s/Brian Rodriguez
                                      -------------------------------
                                      Brian Rodriquez

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]